Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240039/S004

SetPoint System

SetPoint Medical · Decision date Oct 29, 2026

MEDTECHLEDGER EXPLANATIONP240039/S004

What did the FDA decide?

The FDA record shows an approval decision (OK30) dated 2026-10-29 for SetPoint System supplement P240039/S004, filed as a 30-Day Notice with the reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The source statement describes reducing endotoxin monitoring from every lot to quarterly testing, with sampling of at least one lot manufactured each quarter. The record lists the device category as a vagus nerve stimulator for rheumatoid arthritis under product code SFJ.

The identifier establishes this as a supplement to PMA P240039, not a new approval of the whole system. The source statement's stated purpose is a manufacturing monitoring change; it does not present safety or clinical effectiveness data, so the decision record does not itself prove either. The fields supplied give no detail on which manufacturing site, test method, or acceptance criteria the quarterly sampling covers; those specifics are absent from the source.

FDA approval order statement

Approval for reducing endotoxin monitoring from every lot to quarterly, sampling at least one lot manufactured each quarter
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
Oct 29, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240039/S004
Regulatory pathway
PMA supplement
Product code
SFJ
Decision code
OK30
Decision date
Oct 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Vagus nerve stimulator for rheumatoid arthritis.

Product code
SFJ
FDA device class
3

For the original device and its historical approval scope, see PMA P240039. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240039/S004 received

    Application receipt date recorded by FDA.

  2. P240039/S003 · Related supplement

    Charger SetPoint System

  3. P240039/S004 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P240039. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240039

Product / regulatory recordCompanyPathwayDecision dateSource
SetPoint MedicalPMA approvalJul 30, 2025FDA
SetPoint MedicalPMA supplementOct 16, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

SetPoint Medical

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
25101 Rye Canyon Loop, Valencia, CA, 91355

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records